Last reviewed · How we verify
NCT05496634
The Effect of Pilates on Biopsychosocial Characteristics in the Covid-19 Pandemic
NA trial testing Sedantary in COVID-19 in 54 participants. Completed in 21 December 2022.
12 December 2022
Quick facts
| Lead sponsor | Medipol University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 54 |
| Start date | 5 January 2022 |
| Primary completion | 12 December 2022 |
| Estimated completion | 21 December 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Sedantary
- Exercise therapy
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Healthy — all drugs for Healthy →
- Sedentary — all drugs for Sedentary →
- Exercise — all drugs for Exercise →
Sponsor
Medipol University
Who can join
Adults 20 to 50, any sex, with COVID-19 or Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to investigation of biopsychosocial characteristics of individuals who do pilates and sedentary individuals during the COVID-19 pandemic. The study was carried out with 2 groups: individuals ages 20-50,participating in a pilates program for 8 weeks (n:27) and sedentary individuals (n:27). Before starting this study, the groups were assessed for biopsychosocial status with the Cognitive Exercise Therapy Approach- Biopsychosocial Questionnaire (CETA-BQ) , for depression levels with the Beck Depression Inventory (BDI), for covid-19 fear levels with the Coronavirus Anxiety Scale, for their sleep quality with the Pittsburg Sleep Quality Index (PSQI), quality of life was assessed with the Nottingham Health Profile (NHP). After the first evaluation, an informative presentation emphasizing the importance of physical activity during the pandemic process was given to all participants. Individuals in the exercise group also participated in pilates sessions that lasted 50 minutes, 2 days a week for 8 weeks. At the end of 8 weeks, all questionnaires were repeated for both groups.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05496634
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Medipol University trials
Trials by the same sponsor.
- NCT07277803 — Device-Based vs Manual Sensory Training in Low Back Pain · NA · not yet recruiting
- NCT07214636 — Development and Investigation of the ApneaTheraPlay · NA · not yet recruiting
- NCT07534475 — Venous Tourniquet vs. Arterial Tourniquet for Seizure Monitoring in ECT · NA · not yet recruiting
- NCT07534488 — Sacral Erector Spinae Plane Block in Pilonidal Sinus Surgery · NA · not yet recruiting
- NCT07525648 — Comparison of the Effects of Sevoflurane and Desflurane on Optic Nerve Sheath Diameter During Laparoscopic Surgery · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05496634 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medipol University
- Last refreshed: 22 December 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05496634.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing